2 enrolling by invitation. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Enrolling by invitation 2 |
Follow AstraZeneca: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) Eplontersen - Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) | Phase 3 | Enrolling by invitation | Ionis Pharmaceuticals, Inc. | 1400 | 2022-11-30 | 2026-04-17 |
| Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab Durvalumab - Cancer | Phase 3 | Enrolling by invitation | AstraZeneca | 214 | 2022-04-19 | 2026-10-26 |
Amyloidosis (1) · Neoplasms (1)
durvalumab (1) · eplontersen (1)
Argentina (2) · Australia (2) · Belgium (2) · Brazil (2) · Canada (2) · Czechia (2) · France (2) · Germany (2) · Greece (2) · Italy (2) · Japan (2) · Poland (2) · Spain (2) · United Kingdom (2) · United States (2)